Citigroup
SGP icon

Citigroup’s SpyGlass Pharma SGP Stock Holding History

Citigroup’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.9K Sell
456
-4,734
-91% -$117K ﹤0.01% 5142
2026
Q2 		$116K Buy
+5,190
New +$113K ﹤0.01% 4594

Other funds holding SGP

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Citigroup's SGP Position: Q3 2026 in Review

Citigroup reduced its SpyGlass Pharma (SGP) stake by 91% in Q3 2026, selling an estimated $117K and leaving 456 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5142.

Citigroup first reported a position in SGP in Q2 2026 and has held it in 2 quarters since. The position peaked at $116K in Q2 2026. 26 funds tracked by Wall St. Rank hold SGP as of Q3 2026.

  • Citigroup held 456 shares of SpyGlass Pharma worth $11.9K as of Q3 2026.
  • Citigroup sold 4,734 SpyGlass Pharma shares in Q3 2026, an estimated $117K.
  • SpyGlass Pharma made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5142 holding.
  • Citigroup first reported a position in SpyGlass Pharma in Q2 2026 and has held it in 2 quarters since.
  • Citigroup's SpyGlass Pharma position peaked at $116K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.